In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

Other developments include Teva Pharmaceuticals' launch of the first generic version of Victoza, a GLP-1 drug originally approved in 2010 for Type 2 diabetes and later for reducing cardiovascular ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Liraglutide, sold under the brand name Victoza for diabetes ... But, Krumholz noted, the newer GLP-1 drugs, which are given as weekly injections instead of daily ones, have shown stronger benefits ...